Hydroxocobalamin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Hydroxocobalamin |
| DrugBank ID | DB00200 |
| Brand Names (EU) | Cyanokit |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.23% |
Approved Indication (EMA)
Treatment of known or suspected cyanide poisoning. Cyanokit is to be administered together with appropriate decontamination and supportive measures.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | esophageal varices without bleeding | 99.23% | DL |
| 2 | esophageal varices with bleeding | 99.23% | DL |
| 3 | varicose disease | 98.89% | DL |
| 4 | immune-mediated necrotizing myopathy | 98.69% | DL |
| 5 | antisynthetase syndrome | 98.64% | DL |
| 6 | focal myositis | 98.56% | DL |
| 7 | inflammatory myopathy with abundant macrophages | 98.46% | DL |
| 8 | idiopathic eosinophilic myositis | 98.46% | DL |
| 9 | vitamin deficiency disorder | 98.44% | DL |
| 10 | congenital prothrombin deficiency | 98.32% | DL |
| 11 | biotin metabolic disease | 98.07% | DL |
| 12 | osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome | 97.15% | DL |
| 13 | C1 inhibitor deficiency | 96.92% | DL |
| 14 | maternally-inherited mitochondrial myopathy | 96.68% | DL |
| 15 | vitamin B12 deficiency | 96.66% | DL |
| 16 | maternally-inherited mitochondrial dystonia | 96.63% | DL |
| 17 | primary optic atrophy | 96.51% | DL |
| 18 | hypophosphatasia | 96.46% | DL |
| 19 | serpinopathy with toxic serpin polymerization | 96.28% | DL |
| 20 | Steel syndrome | 95.98% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.